GlassScriptPhysician profile
Ervin Anaya
NPI 1841337219
$6,878.36
in general payments reported to CMS, 2019-2025
40 companies · $1,542 in 2025
The $1,542 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,390 · 2020: $690 · 2021: $685 · 2022: $788 · 2023: $673 · 2024: $1,111 · 2025: $1,542.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,288 · Education: $37.38.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,287.77 |
| Education | $37.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $940.53 | 2019-2025 | Ofev, Stiolto Respimat |
| Glaxosmithkline, LLC. | $858.35 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Astrazeneca Pharmaceuticals LP | $800.51 | 2019-2025 | Fasenra, Tezspire, Airsupra |
| Pfizer INC. | $728.69 | 2019-2025 | |
| Mylan Specialty L.P. | $597.55 | 2019-2024 | Yupelri |
| Grifols USA, LLC | $412.35 | 2019-2025 | Prolastin-C Liquid |
| Insmed, INC. | $401.02 | 2019-2025 | Arikayce, Brinsupri |
| Actelion Pharmaceuticals US, INC. | $256.85 | 2020-2025 | Uptravi, Opsumit |
| Genzyme Corporation | $194.50 | 2020-2025 | |
| Novartis Pharmaceuticals Corporation | $152.61 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $137.77 | 2019-2022 | |
| Pulmonx Corporation | $126.03 | 2019 | |
| Sunovion Pharmaceuticals INC. | $125.09 | 2019-2020 | |
| Amgen INC. | $123.03 | 2022-2025 | Tezspire, Tavneos |
| Lilly USA, LLC | $122.32 | 2025 | Zepbound |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $120.75 | 2020-2025 | Dupixent |
| Merck Sharp & Dohme LLC | $93.75 | 2019-2024 | Capvaxive, Recarbrio, Zerbaxa |
| Genentech USA, INC. | $91.62 | 2019-2023 | Xolair |
| Takeda Pharmaceuticals U.S.A., INC. | $86.06 | 2020-2023 | Glassia |
| Csl Behring | $56.46 | 2019-2024 | Kcentra |
| Avadel Cns Pharmaceuticals, LLC | $44.24 | 2023-2024 | Lumryz |
| United Therapeutics Corporation | $35.73 | 2023-2024 | Tyvaso |
| Verona Pharma, INC. | $33.64 | 2025 | Ohtuvayre |
| Jazz Pharmaceuticals INC. | $31.84 | 2020 | |
| Shire North American Group INC | $31.66 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $29.14 | 2023 | Camzyos, Eliquis |
| Pinnacle Biologics, INC | $25.26 | 2024 | Photofrin |
| Chiesi USA, INC. | $24.31 | 2024 | Cleviprex |
| Abbott Laboratories | $20.86 | 2022 | |
| Viatris Specialty LLC | $20.60 | 2025 | Yupelri |
| Bayer Healthcare Pharmaceuticals INC. | $20.07 | 2025 | |
| Sanofi-Aventis U.S. LLC | $19.50 | 2021 | |
| Baxter Healthcare | $19.37 | 2023 | Hillrom - Life 2000 Ventilation System |
| Abbvie INC. | $16.23 | 2022 | |
| Janssen Pharmaceuticals, INC | $15.14 | 2019 | |
| Ambu INC. | $14.65 | 2023 | |
| Fisher & Paykel Healthcare INC | $14.49 | 2025 | Fisher & Paykel Healthcare |
| Mallinckrodt Enterprises LLC | $12.57 | 2019 | |
| Electromed, INC. | $11.85 | 2019 | |
| Philips North America LLC | $11.37 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ervin Anaya listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.